.png){kind=icon}
.png){kind=icon}
Return
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma
.png){kind=icon}
PRE
AI
E
G
M
X
T
C
N
S
H
E
A
M
S
P
DOI：10.1080/17425247.2026.2659263.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The landscape of drug-delivery methods in oncology is evolving, with increased availability of subcutaneous (SC) drug administration options. SC injections reduce treatment duration and enhance patient comfort and satisfaction. However, opportunities exist to improve administration modalities, including enhancing practice efficiency and patient experience, addressing needle-phobia, and reducing physical strain for HCPs related to manual injection. Isatuximab (Isa), an anti-CD38 monoclonal antibody approved for intravenous administration in multiple myeloma (MM), is being investigated across the MM treatment continuum for SC delivery via an innovative on-body injector (OBI; Isa SC OBI). With a small, retractable needle enabling hands-free delivery, the Isa SC OBI has the potential to address gaps in the MM treatment experience.
We conducted a literature search of MEDLINE/PubMed through 2025 for data on the use of an OBI in oncology (through Isa SC OBI), examining its advantages over SC manual or intravenous administration, considerations for clinical practice, ongoing and upcoming clinical trials, and future MM treatment opportunities.
The use of an OBI for the delivery of SC isatuximab could potentially improve clinical workflow, reduce duration of clinical visits and physical burden for HCPs through hands-free administration, and enhance patient experience through the small, hidden needle.
Keywords:
CD38
drug delivery
isatuximab
multiple myeloma
subcutaneous
Journal
IF:
5.4
Papers:
2.3K
Citations:
1.0W
Organization
Cited Papers